Background: A subgroup of patients with common variable immunodeficiency (CVID) experience immune dysregulation manifesting as autoimmunity, lymphoproliferation, and organ inflammation and thereby increasing morbidity and mortality. Therefore treatment of these complications demands a deeper comprehension of their cause and pathophysiology. Objectives: On the basis of the identification of an interferon signature in patients with CVID with secondary complications and a skewed follicular helper T-cell differentiation in defined monogenic immunodeficiencies, we sought to determine the profile of CD4 memory T cells in blood and secondary lymphatic tissues of these patients. Methods: We quantified T H 1/T H 2/T H 17 CD4 memory T cells in blood and lymph nodes of patients with CVID using flow cytometry, analyzed their function, and correlated all findings to the burden of immune dysregulation. Results: Patients with CVID with immune dysregulation had a skewed memory CD4 T-cell differentiation toward a CXCR3 1 CCR6 2 T H 1 phenotype both in blood and lymph nodes. Consistent with our phenotypic findings, we observed a higher IFN-g production in peripheral CD4 memory T cells and lymph node-derived follicular helper T cells of patients with CVID compared with those of healthy control subjects. Increased IFN-g production was accompanied by a poor germinal center output, an accumulation of T-box transcription factor (T-bet) 1 Common variable immunodeficiency (CVID) comprises a heterogeneous group of disorders of hypogammaglobulinemia (www.esid.org). Based on their clinical presentation, they can be divided into patients who present only with infections (common variable immunodeficiency with only infectious complications [CVIDio] ) and those who are additionally affected by various manifestations of immune dysregulation (complex common variable immunodeficiency [CVIDc]), including autoimmune cytopenia, lymphadenopathy, granulomatous disease, interstitial lung disease, and enteropathy, contributing to an increased morbidity and mortality in this frequent subgroup (30% to 50% of patients).
1,2 Regular immunoglobulin replacement therapy significantly reduces the number and severity of bacterial infections but has little effect on immune dysregulation. 3 Therefore patients often receive nonspecific immunosuppressive treatment, potentially aggravating the already impaired host defense. A deeper comprehension of the underlying cause and 
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1 circulating follicular helper T (cTFH) cells toward a T H 1-like phenotype. 4 cTFH cells correlate with tissue follicular helper T (TFH) cells regarding gene expression profile and superior capacity to support antibody production by B cells. 5, 6 They can be delineated into cTFH1, cTFH1/17, cTFH2, and cTFH17 cells with similar master transcription factors, signature cytokines, and chemokine receptor profiles as their non-cTFH counterparts. 4 For example, patients with gain-offunction mutations in signal transducer and activator of transcription 1 (STAT1) or STAT3 present with a relative expansion of CXCR3
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CCR6
2 T H 1-like cTFH cells. Based on these findings and recent whole-blood transcriptional profiling that revealed that patients with CVIDc are characterized by a marked upregulation of interferon-responsive genes, 7 we wondered whether a similar shift of cTFH cells and subsequent increased IFN-g production is present in genetically undefined patients with CVIDc.
Interferon gene signatures of peripheral blood cells have also previously been described in patients with systemic lupus erythematosus, 8 arising from increased type I and II interferon exposure. 9, 10 In a mouse model of lupus, excessive IFN-g was responsible for the accumulation of TFH cells in the germinal center (GC) and autoantibody formation. 11 The reduction or absence of IFN-g signals either by anti-IFN-g treatment 12 or using lupusprone mice lacking IFN-g 13 or its receptor 14 resulted in ameliorated disease, corroborating the role not only of type I but also type II interferons in patients with autoimmunity and end-organ damage.
In this study, for the first time, we demonstrate that in patients with CVIDc with immune dysregulation, the CD4 T-cell differentiation is skewed toward a T H 1 phenotype, leading to overexpression of IFN-g and accumulation of T-box transcription factor (T-bet) 1 B cells both in blood and secondary lymphoid tissues. Our findings provide a pathophysiologic link between the association of CD21 low B-cell expansion in peripheral blood and the clinical phenotype of CVIDc.
METHODS
Human samples
After ethical approval by local authorities (Freiburg 239/1999 and 121/11), written informed consent was obtained from all patients and control subjects. Peripheral blood and tissue samples were obtained from patients with CVID seen at the immunodeficiency clinic of the Freiburg University Medical Center, Freiburg; Charit e, Berlin; or University Hospital, Frankfurt, Germany. All lymph node and tonsil biopsy specimens were performed for medical reasons to exclude malignant lymphoma in patients with lymphadenopathy. Tonsillar control biopsy specimens were obtained from subjects without known immunodeficiency undergoing tonsillectomy. All patients fulfilled the criteria for CVID according to the European Society for Immunodeficiencies (www.esid.org). 15 Next-generation sequencing was performed for 37 of 67 patients and revealed the following heterozygous mutations: nuclear factor kB subtype 1 (NFKB1) K244_D279delinsN (2 patients), NFKB1 V456* (2 patients), NFKB1 E884K, NFKB2 R853C*7, cytotoxic T lymphocyteassociated protein 4 (CTLA4) R75Q, STAT1 V266I, TNFRSF13B I87N, TNFRSF13B C104R, and TNFRSF13B S144* (1 patient each). The following clinical data were recorded: splenomegaly (defined as a diameter of greater than 11 3 4 3 7 cm, as shown by using ultrasonography or computed tomography [CT]); generalized lymphadenopathy (lymph nodes >1 cm in diameter in > _2 different anatomic sites detected by means of clinical examination, ultrasonography, or CT); granulomatous disease (suggested by CT or proved by histology); autoimmune cytopenias (autoimmune hemolytic anemia or thrombocytopenia); interstitial lung disease (based on CT morphology and bronchoalveolar lavage or biopsy); and enteropathy (histology). Patients with CVIDc were defined as having at least 1 of the following secondary complications: generalized lymphadenopathy, granulomatous disease, autoimmune cytopenia, interstitial lung disease, or enteropathy. Patients with CVID having only splenomegaly were assigned to the CVIDio group. Additionally, all patients were classified according to the EUROclass classification.
2 Clinical and immunologic parameters of investigated patients are summarized in Table E1 in this article's Online Repository at www.jacionline.org.
Isolation of PBMCs and mononuclear cells from secondary lymphoid organs
PBMCs were isolated by using Ficoll density centrifugation (Pancoll; PanBiotech, Aidenbach, Germany). Mononuclear cells from secondary lymphoid organs (SLOs) were isolated by means of mechanical disruption. Tissue was minced with a scalpel, and the cell suspension was pressed through a sieve (380-mm mesh) and stored in liquid nitrogen. Untouched memory CD4 (memCD4) T cells were isolated from PBMCs or thawed SLOs by using the memCD4 1 T Cell Isolation Kit, and untouched B cells were isolated from SLOs by using the B cell Isolation Kit II (both from Miltenyi Biotec, Bergisch Gladbach, Germany).
Flow cytometric analysis of T-and B-cell subpopulations
PBMCs and lymph node-derived and tonsillar mononuclear cells were labeled with the respective antibodies for detection of the indicated cellsurface molecules. The gating strategy is shown in Fig E1, A, in this article's Online Repository at www.jacionline.org. Peripheral blood B-cell subpopulations were analyzed, as previously described. 16 Data were acquired on a Gallios flow cytometer (Beckman Coulter, Brea, Calif) or an LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ) and analyzed with FlowJo software (version 7.6.5 or 10; TreeStar, Ashland, Ore).
Statistics
Values were expressed as means 6 SDs. Statistical significance was assessed for data sets with Gaussian distribution by using 1-way ANOVA followed by the Holm-Sidak test to correct for multiple testing or for data sets without Gaussian distribution by using the Kruskal-Wallis test followed by the Dunn multiple correction test, unless specified otherwise. Statistical significance of clinical data was assessed with the Fisher exact test. Results were analyzed with GraphPad Prism software (version 6.07; GraphPad Software, La Jolla, Calif), and P values of less than .05 were considered significant.
Additional information can be found in the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS
Increased percentages of CXCR3
1 CCR6 2 memCD4 T cells in patients with switched memory B 21 low CVID Based on the discovery of an altered distribution of cTFH cells (CXCR5 1 memCD4 T cells) in a subgroup of patients with genetically defined primary immunodeficiencies with hypogammaglobulinemia, we investigated memCD4 T cells in 46 patients of a well-characterized CVID cohort. As previously reported, 17 absolute CD4 T-cell counts affecting especially naive but also memCD4 T cells were reduced (see Fig E2, A, in this article's Online Repository at www.jacionline.org) in patients with CVIDc. Only absolute counts of cTFH cells, derivatives of tissue TFH cells, were comparable and even relatively increased in patients with CVID when compared with those in healthy donors (HDs; see Fig E2, A) .
Detailed analysis of CXCR5 1 cTFH cells (Fig 1, A) and CXCR5
2 (Fig 1, B) memCD4 T cells revealed a significant expansion of CXCR3
1
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2 T H 1 subsets in patients with CVIDc compared with patients with CVIDio and HDs, whereas the frequencies of T H 2 and T H 17 cTFH and CXCR5 2 memCD4 T cells were reduced in patients with CVIDc. Patients with CVIDc more frequently present with an expansion of CD21 low B cells (EUROclass switched memory smB-21low), whereas the CVIDio group consists predominantly of smB-21norm patients in our cohort (P 5 .0021, Fisher exact test). Stratification of patients based on the EUROclass classification confirmed a significant expansion of CXCR3 1 CCR6 2 cTFH cells and CXCR5 2 memCD4 T cells in smB-21low patients compared with smB-21norm patients and HDs, whereas the frequencies of T H 2 and T H 17 cTFH cells and CXCR5 2 memCD4 T cells were reduced in smB-21low patients (Fig 1, C and D) . This was also true for absolute counts of cTFH cells but not for CXCR5 2 memCD4 T cells (see Fig E2, C) . The altered distribution of these subsets in both T-cell compartments was stable during the investigation period (see Fig E3 in this article's Online Repository at www.jacionline.org). In accordance with the observed T H 1 bias in smB-21low patients, mRNA levels of TBX21 (encoding for T-bet, the master regulator of T H 1 cells) in memCD4 T cells were significantly higher in smB-21 low patients than in control subjects and smB-21norm patients (Fig 1, E) . This skewing toward phenotypically T H 1 memCD4 T cells was also evident in SLOs, such as lymph nodes and tonsils, of patients with CVID. CXCR3 1 CCR6 2 T H 1 cells were increased in tonsils from patients with CVID compared with those from control subjects (51.8% 6 23.7% vs 10.64% 6 4.3%), whereas numbers of T H 2 memCD4 T cells, the main subset in tonsils, were significantly reduced (Fig 1, F; for gating, see Fig E1, B) . This T H 1 shift in conventional memory and TFH CD4 T cells was present in all smB21low patients but only half of the smB-21norm patients (Fig 1, F) .
Phenotypic changes are associated with increased IFN-g production in patients with CVID
To confirm augmented IFN-g production in memCD4 T-cell populations of patients with smB-21low CVID, we analyzed the expression of this key cytokine of T H 1 responses by using intracellular flow cytometry. Consistent with our phenotypic findings, a significantly increased proportion of peripheral memCD4 T cells from smB-21low patients produced IFN-g both after anti-CD3/CD28 and phorbol 12-myristate 13-acetate plus ionomycin stimulation (Fig 2, A) . In line with this, IFN-g production was increased in TFH cells (Fig 2, B) and programmed cell death protein 1(PD-1)-positive non-TFH cell populations (see Fig E4, A, in this article's Online Repository at www.jacionline.org) in SLOs of patients with CVID, whereas IL-17A production was reduced (see Fig E4, B) . We also detected higher IFN-g concentrations in serum of patients with CVID, suggesting increased systemic levels, especially in smB-21low patients (Fig 2, C) . To analyze the prevalence and type of secondary complications in patients with CVID with high IFN-g production in vitro, a cutoff was set at 40% IFN-g 1 cells after phorbol 12-myristate 13-acetate plus ionomycin stimulation according to the highest value observed in HDs in this assay. Patients with more than 40% IFN-g 1 cells had a higher burden of autoimmune cytopenia, lymphadenopathy, interstitial lung disease, and enteropathy (Table I ). The prevalence of splenomegaly or granulomatous disease did not differ between the groups.
Effect of IFN-g on GC output
To determine whether a shift toward T H 1 was associated with a decreased GC output, numbers of IFN-g-producing TFH cells in SLOs was compared with numbers of IgD 2
CD38
low classswitched memory B cells in SLOs. High IFN-g production was associated with low numbers of class-switched memory B cells (Fig 3, A) . To investigate a potential negative effect of IFN-g on immunoglobulin production, we stimulated isolated memCD4 T cells from tonsils of HDs and heterologous B cells from tonsils of HDs with staphylococcal enterotoxin B in the presence or absence of IFN-g or blocking antibodies to IFN-g. Exogenous IFN-g decreased immunoglobulin secretion of IgG and IgA, whereas IgM was not affected (Fig 3, B) . Coincubation experiments with isolated B cells and CVID memCD4 T cells from tonsils of HDs did not show a difference compared with HD-derived memCD4 T cells (data not shown).
In addition to altered amounts of total IgG production, cytokines influence the differential expression of IgG subclasses. Therefore we sequenced sorted class-switched memory B cells and plasmablasts from 3 tonsils from HDs and 3 SLOs from patients with CVID. Consistent with previous reports, 18 g1 transcripts were the most abundant transcripts in tonsils from HDs, followed by g3, g2, and g4 (Fig 3, D) . Patient 1 had a comparable IgG subclass distribution, but in patients 2 and 3, both characterized by high IFN-g production in their CD4 T-cell compartment, g2 transcripts were severely reduced.
Increased T-bet expression in lymph nodes from patients with CVID
Compatible with the high IFN-g production by CD4 T cells in SLOs of affected patients with CVID, we found increased numbers of T-bet-expressing cells in the GCs (Fig 4, A) . There was a tendency toward high numbers of T-bet 1 cells, especially in irregularly shaped GCs compared with normal-shaped GCs within the same lymph node (Fig 4, B) . However, the highest T-bet expression was observed in B cells located outside GCs (Fig 1, A and C) and T H 1, T H 1/17, T H 2, and T H 17 (Fig 1, B and D) cell subsets in PBMCs of HDs and patients with CVID. E, Expression of TBX21 in CD4 memory T cells. F, T H 1, T H 1/17, T H 2, and T H 17 subsets in tonsils from HDs and SLOs from patients with CVID. *P < .05, **P < .01, ***P < .005, and ****P < .001. J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 2 near the sinuses (Fig 4, C) . Patients with CVID had significantly more T-bet 1 B cells in the investigated lymph nodes compared with control subjects. The topographic distribution and high T-bet expression suggested that these cells are monocytoid B cells. 19 The typical combination of high expression of Fc receptor-like 4 (FcRL4) and low expression of CD21 corroborated this assumption (Fig 4, D) . T-bet expression was higher in monocytoid B cells from SLOs of patients with CVID compared with those from tonsils of HDs, especially in CD21low patients (Fig 4, E) , which was compatible with a strong T H 1 environment in lymph nodes of smB-21low patients with CVID.
CD21 low B cells are probably direct products of an IFN-g-driven immune environment
The group of patients with a high score of T-bet 1 monocytoid B cells was enriched for patients with high percentages of CD21 low B cells in blood (Fig 5, A) . Interestingly, peripheral blood CD21 low B cells also express FcRL4, a typical marker of monocytoid B cells (Fig 5, B) , suggesting a direct relationship between both B-cell populations. Because prominent monocytoid B-cell expansions have been seen mainly in lymph nodes of patients with T H 1-associated disorders, 20 we hypothesized that there are signs of this IFN-g environment also present in peripheral blood-derived CD21 low B cells. Indeed, CD21 low B cells expressed the highest T-bet levels among circulating B cells (Fig  5, C) , and gene expression profiling of CD21 low B cells revealed an interferon signature (Fig 5, D) , implying a direct link between the IFN-g-associated immune dysregulation and expansion of this unusual B-cell population.
DISCUSSION
Supporting previous findings in defined monogenetic forms of primary immunodeficiency, 4 we observed a T H 1-skewed cTFH cell differentiation in patients with CVIDc. Analysis of SLOs revealed that the predominance of the T H 1 phenotype is not limited to peripheral blood but also manifests directly in TFH cells within GCs. We corroborated this phenotypic finding by demonstrating an increased percentage of IFN-g-producing memory T cells in blood and SLOs and increased IFN-g serum levels. There are conflicting results in regard to IFN-g in patients with CVID. 21 Studies taking into account the heterogeneity of patients with CVID identified a subgroup of patients with low naive CD4 Tcell numbers and increased IFN-g production. 22 Also, in the context of enteropathy, mucosa-infiltrating T cells in patients with CVID are mainly of the T H 1 subset, whereas T H 17 cell numbers are reduced compared with those in patients with Crohn disease. 23 Recently, Cols et al 24 identified an association of increased IFN-g levels with the manifestation of secondary complications in patients with CVID. 24 Also, in our cohort increased serum IFN-g levels were associated with the clinical presentation of CVIDc. Cols et al correlated the IFN-g signature to an expansion of IFN-g-producing innate lymphoid cells. In our cohort we find a T H 1-skewed memCD4 T-cell differentiation associated with this clinical phenotype. This was not only associated with the IFN-g, IFN-g blockade (aIFN-g) , or isotype control (iso) after 5 days. C, Distribution of IgG subclass transcripts in SLOs. *P < .05 and **P < .01. ns, Not significant. manifestation of enteropathy but also autoimmune cytopenia, interstitial lung disease, and lymphadenopathy. Given the abundance of T cells compared with innate lymphoid cells as a source of IFN-g, we assume that T cells contribute substantially to the interferon signature observed in patients with CVIDc.
The underlying mechanism for the skewed differentiation of memCD4 T cells toward a T H 1 phenotype in patients with CVIDc remains to be determined. The TFH phenotype of all defined monogenetic defects with CVID-like disorders could not be distinguished from that of the other patients with CVID in our cohort. We could not detect a more severe humoral immunodeficiency and therefore increased general infection rate in patients with CVIDc versus those with CVIDio. However, expansions of T H 1 cTFH cells are reported in the context of recent viral antigen 
exposure. The expansion of antigen-specific inducible costimulator (ICOS)-expressing CXCR3
1 cTFH cells has been observed after influenza vaccination, 25 as well as in the acute phase of hepatitis C virus (HCV) and EBV infection. 26 In contrast to influenzavaccinated subjects and patients with HCV in whom the numbers of (antigen-specific) ICOS 1 CXCR3 1 cTFH cells return to baseline levels within 6 weeks, we see a stable increase in numbers of T H 1 cTFH cells in patients with CVIDc over months. A similar polarization toward T H 1 affecting the whole memCD4 T-cell compartment 27 and specifically the cTFH compartment 28 is reported for HIV-infected patients during the chronic phase. Moreover, animal models of simian immunodeficiency virus infection in rhesus macaques demonstrated that chronic simian immunodeficiency virus infection promotes expansion of T H 1-biased GC TFH cells, 29 which was similar to our observations in SLOs of patients with CVID. Cubas et al 28 suggested that chronic immune activation drives memory TFH cell polarization toward a T H 1-like phenotype in chronically infected patients with HIV. In our cohort we observed intermittent reactivation of cytomegalovirus or EBV in 9 of 55 patients, whereas in the majority of our patients, a chronic viral infection still remained elusive.
The strongest T H 1 shift of TFH cells was observed in patients with an expansion of circulating CD21 low B cells. Here we show that these cells express the highest levels of T-bet among peripheral blood lymphocytes and carry an interferon signature. This suggests that CVID CD21 low B cells themselves are probably driven by a T H 1 environment and therefore might serve as a marker for T H 1-associated immune dysregulation. This hypothesis is supported by IFN-g-driven induction of age-associated B cells, a murine analog of human CD21 low B cells. 30 Studies in mice suggest that this unique T-bet 1 B-cell population is induced by synergistic signaling through the B-cell receptor, Toll-like receptor 7, and the IFN-g receptor. They arise during viral infection and are essential for efficient viral clearance 30, 31 but also participate in the pathogenesis of autoimmune reactions in lupus-prone mice. 32, 33 Interestingly, the same association has been observed for human CD21 low B cells, which are found not only in peripheral blood of patients with CVID 34 but also in patients with autoimmune diseases, such as rheumatoid arthritis 35 and systemic lupus erythematosus, 36, 37 as well as in patients with chronic infections, such as HIV, 38 HCV, 39 and malaria. 40 The evolving common pattern of the immune pathogenesis in these disorders is summarized in Table II. 20,26-28,38-51 Although originally we had not found the equivalent of these cells in lymph nodes of patients with CVID, 34 an optimized marker combination and T-bet expression demonstrated that sinusoidal B cells are the closest related population, which probably overlap with FcRL4 1 tissue memory-like B cells 52 and morphologically described monocytoid B cells. 53 The pathologic increase in numbers of T-bet 1 B cells in the lymph nodes of patients with CVID resembles findings in the context of T H 1 immune responses against intracellular pathogens, such as HIV and toxoplasma 20 and in the placentas of malaria-infected women. 41 Interestingly, for several of these diseases, the presence of irregularly shaped GCs has been described (Table II) , proposing a potential association between the T H 1 milieu and GC morphology, which needs further explanation. Here, for the first time, we were able to describe both circulating B and memCD4 T cells and SLO-derived B and TFH cells of the same patient in the setting of CVID, linking alterations of both compartments.
We found a negative correlation between the amount of IFNg-producing TFH cells in SLOs and the presence of classswitched memory B cells in patients with CVID, suggesting a negative influence of T H 1-polarized TFHs on B-cell memory formation. There is evidence from other diseases, such as HIV 54 and malaria, 42 that CXCR3 1 cTFH cells (consisting of cTH1 and cTH1/17 cells) are less efficient B-cell helpers compared with CXCR3 2 cTFH cells (consisting of cTH2 and cTH17 cells), resulting in suboptimal specific antibody responses. In line with this idea, our in vitro experiments corroborated that exogenous IFN-g reduces IgG and IgA production in B/T-cell cocultures. 28, 55 The cytokine milieu impacts class-switching. 56 This is well established in murine models, where IFN-g induces g2 transcripts and IL-4 induces g1 and ε transcripts. 57 Similarly, IL-4 induces IgG 4 and IgE secretion in human B cells, 58 but to our knowledge, no specific human IgG subclass has been linked with IFN-g. Analysis of antibodies directed against viral proteins revealed an IgG 1 /IgG 3 predominance and an IgG 2 predominance against polysaccharides. 59 In this study we observed a selective reduction of g2 transcripts in class-switched memory B cells and plasmablasts of patients with T H 1-biased TFH cells, whereas the patient with CVID with a normally distributed TFH compartment expressed all g-transcripts at levels comparable with those in control subjects. A similar skewing of IgG subclasses with reduced IgG 2 levels is common in HIV-infected patients, 60 whose memCD4 T-cell compartment is also T H 1 biased, as discussed above. 27, 28 It is remarkable in this context that we observed preexisting IgG 2 /IgG 4 subclass deficiencies in 4 patients with full CVID with a T H 1-like environment. Further studies will need to verify the hypothesis that a T H 1 bias in GCs is the underlying cause of IgG 2 /IgG 4 deficiency. In addition, it will be interesting to test whether a constellation of IgG 2 /IgG 4 deficiency, an expansion of CD21 low B cells and T H 1 bias might be able to identify patients with CVID who are prone to manifestations of immune dysregulation and should be monitored more closely in this respect.
In summary, for the first time, we demonstrated that patients with CVIDc harbor a T H 1-biased CD4 compartment both in blood and in secondary lymphoid tissues. This mirrors recent reports that linked CD4 T cells with a T H 1 phenotype to the development of autoimmune manifestations in patients with diabetes mellitus 61 and rheumatoid arthritis. 62 Our results provide a pathophysiologic link between the abundance of IFNg-producing TFH cells, the expansion of CD21 low B-cell numbers in peripheral blood, and the clinical phenotype of CVIDc. We suggest that CD21 low B-cell expansion might serve as a biological marker for a T H 1-associated immune dysregulation in patients with CVIDc and that IgG 2 /IgG 4 subclass deficiency might be linked to this immune dysregulation.
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Clinical implications: Patients with CVID with secondary complications and an expansion of CD21 low B cells need to be evaluated for causes of a T H 1-associated pathophysiology. This rationale might offer new targeted therapeutic avenues. Not known
